Natasha Rekhtman

Targets

• DLL3 1
• EGFR 1
• STK11 1
• YAP 1

Filled chips are declared by the researcher; the others come from publications (number of works).

Now

Trials, publications and grants since Nov 2024.

• Publication

  De Novo Germline L858R EGFR Variants and Generalized Acanthosis Nigricans.

  JAMA dermatology, Mar 2026

• Publication

  Primary Pulmonary Ameloblastoma: First Case Series With Clinicopathologic and Genomic Analysis.

  The American journal of surgical pathology, Jan 2026

• Publication

  Pulmonary Solid and Granular Adenocarcinomas Expressing HepPar1/CPS1: Highly Aggressive Tumors Exhibiting Mitochondrial Adaptation to STK11 Mutations Rather Than Hepatoid Differentiation.

  Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, Jan 2026

• Publication

  Analysis of SCLC subtype markers (ASCL1, NEUROD1, POU2F3, YAP1), DLL3, OTP, and TTF1 in 300 lung carcinoids and enteropancreatic neuroendocrine tumours.

  Histopathology, Jan 2026

• Publication

  Delta-Like Ligand 3 Expression and Functional Imaging in Gastroenteropancreatic Neuroendocrine Neoplasms.

  JCO precision oncology, Nov 2025

Affiliations

• Memorial Sloan Kettering Cancer Center

Co-authors

• OBOlca BasturkHow are we linked?

Who links you

Enter another researcher's profile link or ID to see who has published with both of you.